Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof

Patent metadata

Field	Value
Publication number	US-10351522-B2
Application number	US-201615735835-A
Country	US
Kind code	B2
Filing date	Jun 10, 2016
Priority date	Jun 12, 2015
Publication date	Jul 16, 2019
Grant date	Jul 16, 2019

Abstract

The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I):

wherein each symbol is as defined in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.

First claim

The invention claimed is:

1. A compound represented by the formula (I):

wherein
R 1 is a hydrogen atom, C 1-6 alkoxy, —OH, C 1-6 alkyl or a halogen atom,
X is —C(R 5 )═ or —N═,
R 5 is a hydrogen atom or C 1-6 alkoxy,
any one of R 2 , R 3 and R 4 is R 6 and the remaining two are each a hydrogen atom,
R 6 is
(1) —NR 17 —Y 1 —R 7
wherein Y 1 is —C(═O)NR 18 —, —C(═S)NH—, —C(═NH)NH—, —C(═O)O—, —C(═O)—, —SO 2 — or —SO 2 —NR 8 —,
R 8 is a hydrogen atom or C 1-6 alkyl,
R 17 is a hydrogen atom or C 1-6 alkyl,
R 18 is a hydrogen atom or C 1-6 alkyl, or
R 17 and R 18 are optionally bonded to each other to form, together with the nitrogen atoms bonded thereto and adjacent C(═O), a 5- to 7-membered heterocycle,
R 7 is
(a) C 6-10 aryl,
(b) 5- to 10-membered heteroaryl,
(c) C 1-6 alkyl, or
(d) C 2-6 alkenyl
wherein C 1-6 alkyl and C 2-6 alkenyl are optionally substituted by one substituent selected from phenyl, furyl and diphenylmethylsulfinyl,
C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted by optionally selected R 9 in the number of 1 to 4,
R 9 are each independently
a halogen atom,
—NO 2 ,
—OH,
C 1-6 alkyl,
C 1-6 haloalkyl,
C 1-6 alkoxy,
5- to 10-membered heteroaryl,
—NR 9a R 9b wherein R 9a is a hydrogen atom, C 1-6 alkyl or C 1-6 alkoxy-carbonyl, and R 9b is a hydrogen atom or C 1-6 alkyl,
—C(═O)OR 9c wherein R 9c is a hydrogen atom or C 1-6 alkyl,
—C(═O)NR 9d R 9e wherein R 9d is a hydrogen atom or C 1-6 alkyl, and R 9e is a hydrogen atom or C 1-6 alkyl, or
—NH—C(═NR 9f )—NHR 9g wherein R 9f is a hydrogen atom or C 1-6 alkoxy-carbonyl, and R 9g is a hydrogen atom or C 1-6 alkoxy-carbonyl, or
R 9 in the number of 2 are joined to form methylenedioxy,
(2) —NH—Y 2 —R 10
wherein Y 2 is —CH 2 — or a single bond, and
R 10 is
(a) C 6-10 aryl, or
(b) 5- to 10-membered heteroaryl
wherein C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted by optionally selected R 9 in the number of 1 to 4, and R 9 is as defined above,
(3) a group represented by the formula (ii):

wherein R 11 is C 1-6 alkoxy or C 6-10 arylamino (wherein C 6-10 aryl moiety of the C 6-10 arylamino is optionally substituted by 1 to 3 substituents selected from C 1-6 alkyl and C 1-6 alkoxy),
(4) —N═N—R 12
wherein R 12 is C 6-10 aryl optionally substituted by 1 to 3 substituents selected from (a) C 1-6 alkyl optionally substituted by —OH, (b) —OH, (c) di(C 1-6 alkyl)amino and (d) C 1-6 alkoxy-carbonylamino, or
(5) —NR 13 R 14
wherein R 13 is a hydrogen atom, C 1-6 alkyl, C 6-10 aryl-C 1-6 alkyl or C 2-6 alkenyl-carbonyl, and
R 14 is a hydrogen atom or C 1-6 alkyl (wherein C 1-6 alkyl is optionally substituted by one substituent selected from (a) C 2-6 alkenyl-carbonylamino and (b) C 6-10 aryl-C 1-6 alkylaminocarbonyl optionally substituted by C 1-6 alkyl), or R 13 and R 14 are bonded to each other to form, together with the nitrogen atom bonded thereto, a 5- to 7-membered heterocycle further containing one nitrogen atom (wherein 5- to 7-membered heterocycle is optionally substituted by C 6-10 aryl-carbonyl optionally substituted by C 1-6 alkyl),
provided that when R 14 is ethyl substituted by C 2-6 alkenyl-carbonylamino, R 13 is not a hydrogen atom, and
W is
a group represented by the formula (iii):

wherein R 15 is C 1-6 alkyl, and R 16 is C 1-6 alkyl,
or a pharmaceutically acceptable acid addition salt thereof.

2. The compound according to claim 1 wherein R 17 and R 18 are each a hydrogen atom, or a pharmaceutically acceptable acid addition salt thereof.

3. The compound according to claim 1 wherein X is —C(R 5 )═, wherein R 5 is a hydrogen atom or C 1-6 alkoxy, or a pharmaceutically acceptable acid addition salt thereof.

4. The compound according to claim 1 wherein R 2 is R 6 (wherein R 6 is as defined in claim 1 ), and R 3 and R 4 are each a hydrogen atom, or a pharmaceutically acceptable acid addition salt thereof.

5. The compound according to claim 1 wherein R 6 is —NR 17 —Y 1 —R 7 (wherein R 17 , Y 1 and R 7 are as defined in claim 1 ), or a pharmaceutically acceptable acid addition salt thereof.

6. The compound according to claim 1 wherein R 6 is —NH—Y 2 —R 10 (wherein Y 2 and R 10 are as defined in claim 1 ), or a pharmaceutically acceptable acid addition salt thereof.

7. The compound according to claim 1 wherein R 6 is a group represented by the formula (ii):

wherein R 11 is as defined in claim 1 , or a pharmaceutically acceptable acid addition salt thereof.

8. The compound according to claim 1 wherein R 6 is —N═N—R 12 (wherein R 12 is as defined in claim 1 ), or a pharmaceutically acceptable acid addition salt thereof.

9. The compound according to claim 1 wherein R 6 is —NR 13 R 14 (wherein R 13 and R 14 are as defined in claim 1 ), or a pharmaceutically acceptable acid addition salt thereof.

10. The compound according to claim 1 wherein W is a group represented by the formula (iii):

wherein
R 15 is C 1-6 alkyl and R 16 is C 1-6 alkyl,
X is —C(R 5 )═ wherein R 5 is a hydrogen atom or C 1-6 alkoxy,
R 2 is —NH—Y 1 —R 7 wherein Y 1 and R 7 are as defined in claim 1 , and
R 3 and R 4 are each a hydrogen atom,

or a pharmaceutically acceptable acid addition salt thereof.

11. The compound according to claim 10 wherein Y 1 is —C(═O)NH—, —C(═S)NH—, —C(═NH)NH— or —C(═O)O—, or a pharmaceutically acceptable acid addition salt thereof.

12. A compound represented by the formula (I-B):

wherein R 7a is phenyl substituted by —NR 9a R 9b (wherein R 9a is C 1-6 alkyl and R 9b is C 1-6 alkyl),
R 1 is a hydrogen atom, C 1-6 alkoxy, —OH, C 1-6 alkyl or a halogen atom,
R Wa is C 1-6 alkyl (wherein C 1-6 alkyl is optionally substituted by phenyl, pyridyl, C 1-6 alkoxy-carbonylamino or di(C 1-6 alkyl)amino) or phenyl (wherein phenyl is optionally substituted by di(C 1-6 alkyl)amino), and
R Wb is a hydrogen atom or C 1-6 alkyl,

or a pharmaceutically acceptable acid addition salt thereof.

13. A compound represented by the formula (I′):

wherein
R 1 is a hydrogen atom, C 1-6 alkoxy, —OH, C 1-6 alkyl or a halogen atom,
X is —C(R 5 )═ or —N═,
R 5 is a hydrogen atom or C 1-6 alkoxy,
R 6a is an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, a group bon

Assignees

• Univ Tsukuba
• Univ Texas

Inventors

• Nagase Hiroshi
• Yanagisawa Masashi
• Saitoh Tsuyoshi
• Kutsumura Noriki
• Irukayama Yoko

Classifications

• C07C335/20

  being further substituted by nitrogen atoms, not being part of nitro or nitroso groups · CPC title

• C07D417/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• A61K31/4409

  only substituted in position 4, e.g. isoniazid, iproniazid · CPC title

• C07C317/44

  having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton · CPC title

• A61K31/4402

  only substituted in position 2, e.g. pheniramine, bisacodyl · CPC title